830 related articles for article (PubMed ID: 23603305)
1. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F
J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
[TBL] [Abstract][Full Text] [Related]
4. Long-term benefit of first-line peri-implantable cardioverter-defibrillator implant ventricular tachycardia-substrate ablation in secondary prevention patients.
Acosta J; Cabanelas N; Penela D; Fernández-Armenta J; Andreu D; Borràs R; Korshunov V; Cabrera M; Vasanelli F; Arbelo E; Guasch E; Martínez M; Tolosana JM; Mont L; Berruezo A
Europace; 2017 Jun; 19(6):976-982. PubMed ID: 27353322
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378
[TBL] [Abstract][Full Text] [Related]
6. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
[TBL] [Abstract][Full Text] [Related]
7. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
[TBL] [Abstract][Full Text] [Related]
9. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention.
Streitner F; Kuschyk J; Dietrich C; Mahl E; Streitner I; Doesch C; Veltmann C; Schimpf R; Wolpert C; Borggrefe M
Clin Cardiol; 2011 Oct; 34(10):604-9. PubMed ID: 21887690
[TBL] [Abstract][Full Text] [Related]
11. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
[TBL] [Abstract][Full Text] [Related]
12. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
[TBL] [Abstract][Full Text] [Related]
13. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial.
Al-Khatib SM; Daubert JP; Anstrom KJ; Daoud EG; Gonzalez M; Saba S; Jackson KP; Reece T; Gu J; Pokorney SD; Granger CB; Hess PL; Mark DB; Stevenson WG
J Cardiovasc Electrophysiol; 2015 Feb; 26(2):151-7. PubMed ID: 25332150
[TBL] [Abstract][Full Text] [Related]
14. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.
Cantero-Pérez EM; Sobrino-Márquez JM; Grande-Trillo A; Lage-Gallé E; Rangel-Sousa D; Esteve-Ruiz IM; Martínez-Martínez A
Transplant Proc; 2013; 45(10):3659-61. PubMed ID: 24314988
[TBL] [Abstract][Full Text] [Related]
15. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
Olde Nordkamp LR; Wilde AA; Tijssen JG; Knops RE; van Dessel PF; de Groot JR
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):91-100. PubMed ID: 23275262
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.
Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL
Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978
[TBL] [Abstract][Full Text] [Related]
17. Influence of clinical and procedural predictors on ventricular tachycardia ablation outcomes: an analysis from the substrate mapping and ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial (SMASH-VT).
Tung R; Josephson ME; Reddy V; Reynolds MR;
J Cardiovasc Electrophysiol; 2010 Jul; 21(7):799-803. PubMed ID: 20132389
[TBL] [Abstract][Full Text] [Related]
18. Impact of preventive substrate catheter ablation on implantable cardioverter-defibrillator interventions in patients with ischaemic cardiomyopathy and infarct-related coronary chronic total occlusion.
Žižek D; Mrak M; Jan M; Zupan Mežnar A; Ivanovski M; Žlahtič T; Kajdič N; Antolič B; Klemen L; Skale R; Avramovič Gregorič J; Štublar J; Pernat A; Šinkovec M
Europace; 2024 May; 26(5):. PubMed ID: 38657209
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
[TBL] [Abstract][Full Text] [Related]
20. Heart rate turbulence predicts ICD-resistant mortality in ischaemic heart disease.
Marynissen T; Floré V; Heidbuchel H; Nuyens D; Ector J; Willems R
Europace; 2014 Jul; 16(7):1069-77. PubMed ID: 24196450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
